PEN2 (Presenilin Enhancer 2) is a critical subunit of the gamma-secretase complex, an intramembrane protease that plays a central role in Alzheimer's disease (AD) pathogenesis by cleaving the Amyloid Precursor Protein (APP) to generate amyloid-beta (Aβ) peptides [1][2]. PEN2, encoded by the PSENEN gene, is essential for the assembly, maturation, and catalytic activity of the gamma-secretase complex. First identified in genetic screens for presenilin enhancers, PEN2 has emerged as a key therapeutic target for modulating Aβ production in AD [3].
| Attribute | Value |
|---|---|
| Protein Name | Presenilin Enhancer 2 |
| Gene Symbol | PSENEN |
| UniProt ID | Q9BYH1 |
| Molecular Weight | 12.5 kDa |
| Subcellular Localization | Endoplasmic reticulum, Golgi apparatus, Plasma membrane |
| Protein Family | Gamma-secretase complex subunit |
| Chromosome | 19q13.12 |
| Expression | Ubiquitous, high in brain (cortex, hippocampus) |
PEN2 is a small membrane protein with distinct structural features [3:1][4]:
N-terminal domain (residues 1-50):
Transmembrane domain (residues 51-73):
C-terminal domain (residues 74-101):
PEN2 combines with three other essential subunits to form the active gamma-secretase protease [2:1]:
| Subunit | Gene | UniProt | Role |
|---|---|---|---|
| Presenilin-1 | PSEN1 | P49768 | Catalytic aspartyl protease |
| Presenilin-2 | PSEN2 | O00287 | Alternative catalytic subunit |
| Nicastrin | NCT | Q15118 | Substrate recognition and binding |
| APH-1 | APH1A/APH1B | Q9Y5J9/Q9Y6M4 | Complex stabilization and assembly |
| PEN2 | PSENEN | Q9BYH1 | Essential for PSEN endoproteolysis and activation |
Cryo-EM structures of human gamma-secretase have revealed [3:2]:
Gamma-secretase performs regulated intramembrane proteolysis (RIP) on numerous substrates [2:2][5]:
| Substrate | Cleavage Product | Normal Function |
|---|---|---|
| APP | Aβ peptides (Aβ40, Aβ42, Aβ43) | Unknown physiological role |
| Notch1-4 | Notch intracellular domain (NICD) | Cell fate, development |
| Cadherins | C-terminal fragments | Cell adhesion, signaling |
| ErbB4 | E4ICD | Neural development |
| Jagged | Jagged intracellular domain | Notch ligand signaling |
| IL-1R2 | IL-1R2 ICD | Immune regulation |
| CD44 | CD44 ICD | Cell migration |
PEN2's central role in AD is through Aβ production [6][7]:
| Species | Length | Aggregation | Abundance | Toxicity |
|---|---|---|---|---|
| Aβ40 | 40 aa | Low | ~90% | Lower |
| Aβ42 | 42 aa | High | ~10% | Higher |
| Aβ43 | 43 aa | Very high | ~1-5% | Highest |
Most early-onset familial AD mutations occur in PSEN1 and PSEN2:
Broad-spectrum inhibitors have been developed but face challenges [9][10]:
| Drug | Status | Challenge |
|---|---|---|
| Semaglintat (LY450139) | Discontinued (Phase III) | Notch-related toxicity |
| Avagacestat (BMS-708163) | Discontinued | Notch side effects |
| PF-3084014 | Preclinical | Selectivity issues |
More selective approaches focus on modulating rather than inhibiting [11]:
| Approach | Mechanism | Status |
|---|---|---|
| NSAID-derived (e.g., Flurbiprofen) | Allosteric modulation | Clinical trials |
| E2012 | Preferentially reduce Aβ42 | Phase II |
| CHF5074 | Aβ42 reduction | Clinical trials |
Newer approaches aim to separate APP and Notch processing:
PEN2 plays essential roles in gamma-secretase biogenesis [4:1]:
The aspartyl protease activity of gamma-secretase:
Multiple levels of gamma-secretase regulation:
| Partner | Interaction | Functional Consequence |
|---|---|---|
| Presenilin | Direct binding | Catalytic complex formation |
| APH-1 | Complex assembly | Complex stability |
| Nicastrin | Complex formation | Substrate recognition |
| γ-secretase modulators | Allosteric | Activity modulation |
Gamma-secretase components as biomarkers:
PEN2 expression levels and post-translational modifications hold promise as diagnostic biomarkers for Alzheimer's disease:
PEN2 represents a strategic target for AD drug development:
Historical context for gamma-secretase targeting:
| Compound | Target | Phase | Outcome |
|---|---|---|---|
| Semaglintat | Gamma-secretase | Phase III | Discontinued - Notch toxicity |
| Avagacestat | Gamma-secretase | Phase II | Discontinued - GI toxicity |
| Begacestat | Gamma-secretase | Phase I | Discontinued |
Lessons learned inform current approaches focusing on substrate-specific modulation rather than broad inhibition.
Several key questions remain regarding PEN2 biology and therapeutic targeting:
Recent advances in gamma-secretase biology continue to inform PEN2 research:
Gamma-secretase as a therapeutic target for Alzheimer's disease. 2010. ↩︎ ↩︎ ↩︎
An atomic structure of human gamma-secretase. 2015. ↩︎ ↩︎ ↩︎
PEN2 in amyloid-beta production and neuronal function. 2022. ↩︎
Gamma-secretase inhibitors and modulators in clinical trials. 2021. ↩︎
Gamma-secretase in Alzheimer's disease pathogenesis. 2022. ↩︎
Gamma-secretase modulators reduce toxic Aβ species. 2020. ↩︎
PEN2 phosphorylation and gamma-secretase regulation. 2021. ↩︎
PEN2 endoproteolysis and gamma-secretase maturation. 2019. ↩︎